A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)

Gruenwald, Viktor; Hilser, Thomas; Meiler, Johannes; Goebell, Peter J.; Ivanyi, Philipp; Strauss, Arne; Hartmann, Arndt; Bedke, Jens; Bergmann, Lothar

dc.contributor.author	Bedke, Jens
dc.date.accessioned	2023-06-20T09:24:00Z
dc.date.available	2023-06-20T09:24:00Z
dc.date.issued	2022
dc.identifier.issn	2296-5270
dc.identifier.uri	http://hdl.handle.net/10900/142349
dc.language.iso	en	de_DE
dc.publisher	Karger	de_DE
dc.relation.uri	http://dx.doi.org/10.1159/000522043	de_DE
dc.subject.ddc	610	de_DE
dc.title	A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230202000000_03316
utue.publikation.seiten	272-280	de_DE
utue.personen.roh	Gruenwald, Viktor
utue.personen.roh	Hilser, Thomas
utue.personen.roh	Meiler, Johannes
utue.personen.roh	Goebell, Peter J.
utue.personen.roh	Ivanyi, Philipp
utue.personen.roh	Strauss, Arne
utue.personen.roh	Hartmann, Arndt
utue.personen.roh	Bedke, Jens
utue.personen.roh	Bergmann, Lothar
dcterms.isPartOf.ZSTitelID	Oncology Research and Treatment	de_DE
dcterms.isPartOf.ZS-Issue	5	de_DE
dcterms.isPartOf.ZS-Volume	45	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE